Ketamine-Induced Brain Activity Changes

3 drugs in development·2 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
tak-063	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-063	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 1(1)

Drug	Company
tak-063	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

BioSniper tracks 3 drugs in development for Ketamine-Induced Brain Activity Changes across 2 companies.

There are 1 clinical trial targeting Ketamine-Induced Brain Activity Changes tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.